Comparative Pharmacology
Head-to-head clinical analysis: CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER versus VERARING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE IN 5 0 DEXTROSE IN PLASTIC CONTAINER versus VERARING.
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER vs VERARING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It causes vasodilation and decreases systemic vascular resistance.
Not available
Intravenous infusion: initial dose 5 mg/hour, titrate by 2.5-5 mg/hour every 15-30 minutes as needed; maximum 15 mg/hour. Oral: 20 mg three times daily initially, then 30-40 mg three times daily.
No established standard dosing. Veraring is not a recognized pharmaceutical agent.
None Documented
None Documented
2 to 4 hours in healthy subjects; increased in hepatic impairment (up to 7 hours) and in elderly. No significant change in renal impairment.
Terminal elimination half-life: 4.5 hours (range 3.5-6.0 hours). Clinical context: Steady state achieved within 24 hours; no accumulation with normal renal function.
Primarily hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for approximately 60-70% of total elimination, with renal excretion of metabolites approximately 30-40%.
Renal elimination of unchanged drug and metabolites: 70% (60% unchanged, 40% as glucuronide conjugate); biliary/fecal: 30% (primarily metabolites).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker